Strategic Partnerships Scailyte's AI-driven biomarker discovery platform ScaiVision, with access to oncology and autoimmune patient cohorts and a network of clinical partners, offers pharma and biotech a path to co-develop biomarker signatures and companion diagnostics for precision medicine across global clinical programs.

Cohort Advantage The company's unique single-cell data assets—over tens of millions of profiles—support patient stratification and enrichment strategies in clinical trials, enabling partners to improve trial outcomes and reduce failure rates.

Global Growth With leadership expansion including a US-based Chief Business Officer and an Executive Chair, Scailyte is positioned to engage US and global markets, offering biomarker discovery services and collaboration opportunities for drug development across regions.

AI IP Edge ScaiVision's proprietary AI platform and patent-pending biomarker signatures provide a defensible differentiation for customers seeking precision medicine solutions, creating a potential for licensing, co-development, or extended datasets with large pharma and CROs.

Funding Momentum Recent government-backed funding from Innosuisse reinforces credibility and offers a joint development pathway for partners to access public grants, de-risk early projects, and accelerate biomarker-driven programs.